Service Providers Adapting to Meet Today’s Needs

 

Service providers of the past may have had the luxury of time. While new technologies constantly are emerging, implementing those technologies or streamlining their processes was something that could wait.

In today’s marketplace, however, that simply isn’t the case, said Kyle Siniard, VP of Technology for 3-GIS

“There’s no longer an appetite to wait six to 12 months for some new piece of equipment or for some new requirement inside my network design or how I’m provisioning things,” Siniard said. “As I start to adjust those things, I need to do it right now because, if I don’t do it right now, someone else is, and I can’t get behind. I need to be the first one here, and [I] need to go get these new customers and sign them up. In order to do that, I have to be able to adjust to meet the needs of today.

Companies like 3-GIS can get companies up to speed by providing the systems to get optimized data models and real-time information, whether it be an industry giant like Verizon with 70 different locations or a much smaller operation

“I have 70 different, almost, projects going on and being run in a different format. I then have 20 different vendors managing these markets, so, even organizationally, the businesses I’m working with operate slightly differently. Then, I have 5,000 users or more across all those 70 markets, 20 vendors and my internal team,” he said. “In an eight-month period, we took all those different markets, different vendors and all of those users, and we converted that data and moved them into a single system – a unified data model. That data model is maintaining almost 85,000 geospatial files, it’s got 25,000 fiber miles … and then, in terms of the sheer volume of data, it’s over 130 million different records.

Smaller service providers may have different challenges, but those are tasks 3-GIS is ready to take on and handle with the experience and expertise garnered in working with some of the biggest providers in the world.

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More